Clinical Trial Update: A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating varlilumab in combination with the IMA950 vaccine and Poly-ICLC in adults with WHO grade II low-grade glioma; the study was terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma Grade Ii
• Low-grade Glioma
• Oligoastrocytoma
• Oligodendroglioma

Drugs mentioned

• IMA950 vaccine (IMA-950)
• Poly-ICLC (poly-ICLC)
• Varlilumab (varlilumab)

Snippet

Sponsor: Nicholas Butowski | Conditions: Glioma, Malignant Glioma | Phase 1 | Status: TERMINATED | Results posted: 2024-06-14